secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001654954-23-010239
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin: Fosun reports first Vyleesi sale in China; Kwangdong completes Phase 3 enrollment
--------------------------------------------------------------------------------

- Fosun dispensed first Vyleesi prescription in Hainan Province, China.
- Kwangdong completed Phase 3 enrollment: 193 patients enrolled, 180 completed (93%).
- Data from Korea trial expected by year end; potential MFDS submission in H1 2024.
- Palatin eligible for up to $92.5M in milestones from Fosun plus royalties; $3M milestone from Kwangdong.
- Vyleesi is only FDA-approved as-needed HSDD treatment; Palatin reported six consecutive quarters of double-digit prescription growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495423010239/0001654954-23-010239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495423010239/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-010239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer